[1]Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail, 04 October 2024 [2]国家心血管病中心,国家心血管病专家委员会心力衰竭专业委员会,...
来源: [1]Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail, 04 October 2024 [2]国家心血管病中心,国家心血管病专家委员会心力衰竭专业委员会,中国医师协会心力衰竭专业委员会,《中华心力衰竭和心肌病杂志》编辑...
Pitt B, Velazquez EJ; TRANSFORM-HF Investigators. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023
TRANSFORM-HF研究新分析 目前,充血仍然是心衰患者住院的主要原因,其中大多数患者接受袢利尿剂治疗。尽管指南建议使用最低剂量利尿剂来恢复及维持正常的血容量状态,但在临床实践中充血缓解策略以及利尿剂种类选择和剂量往往由临床医生自行决定。 近期,欧洲心衰杂志发表的一项针对TRANSFORM-HF研究的事后分析发现,在心衰住院患者...
1. TRANSFORM-HF trial found no difference in effectiveness between 2 common loop diuretics.American Heart Association Scientific Sessions 2022, Abstract 17822 2. No difference in heart outcomes found in use of two diuretics to treat blood pressure.American Heart Association Scientific Sessions 2022, Ab...
A NuPulse Trial Patient The NuPulse Difference NuPulse is working to radically change the management and treatment of chronic heart failure. The NuPulse Voyage is the only minimally invasive heart pump that allows patients to be discharged home, where they can recover, adjust to medications and ...
R AHA 2022: Torsemide Comparison With Furosemide for Management of Heart Failure - TRANSFORM-HF Trial By AHA 2022 Conference Coverage FEATURING Robert Mentz November 21, 2022 Comments 3 Login to view comments. Click here to Login
An announcement on partners to collaborate in the TRANSFORM trial was made today during the American Heart Association’s (AHA) 2023 Scientific Sessions. Data from the randomized control trial will advance evidence for evaluation and treatment of heart d
Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, announced the TRANSFORM trial at the American Heart Association’s 2023 Scientific Sessions.
1. TRANSFORM-HF trial found no difference in effectiveness between 2 common loop diuretics.American Heart Association Scientific Sessions 2022, Abstract 17822 2. No difference in heart outcomes found in use of two diuretics to tr...